Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.
Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.
We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.
In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months. Request Insights
IN THE NEWSFeb 24, 2017: Researchers from John Hopkin University reviewed the trials of PDE-5 inhibitors in pediatric patients with pulmonary hypertension. The researchers concluded that PDE-5 inhibitors can be safely prescribed to infants, neonates, and children with primary and secondary pulmonary hypertension
Introduction to Phosphodiesterase Inhibitors
Phosphodiesterase (PDE) inhibitors are termed as therapeutic agents that target PDE isoenzymes and prevents the metabolism of the secondary messengers (cyclic adenosine monophosphate, cyclic guanosine monophosphate) and prolonging the biological effect. Theophylline and papaverine are the two broadly used non-selective phosphodiesterase enzyme inhibitors and are widely accepted to treat various diseases such as cardiovascular, respiratory, and erectile dysfunction. Distinct distribution of all the types of isoenzymes has provided possibilities for selective target therapies. The introduction of selective phosphodiesterase enzyme inhibitors leads to a great impact on the medical treatment sector. Phosphodiesterase superfamily is complex, large, contains one of four genes, and represents 11 gene families from phosphodiesterase 1 to phosphodiesterase 11. The enzymes are found in plasma membranes, cytosol, nuclear membranes, endoplasmic reticulum, and the cytoskeleton.
Market Size and Forecast
The global phosphodiesterase inhibitors market is projected to register a significant rise on account of the escalating prevalence of erectile dysfunction by various factors such as hypertension, obesity, testosterone deficiency, diabetes mellitus, and consumption of certain substance abuse and medications can lead to erectile dysfunction. According to the World Health Organization (WHO), about 150 million people have been affected by erectile dysfunction and this is projected to reach 230 million by 2025. It is a common medical condition affecting about 15% of men each year. Moreover, increasing cases of chronic diseases such as stroke, chronic obstructive pulmonary disease, heart diseases, pre-diabetes, and diabetes are estimated to support the development of phosphodiesterase inhibitors. CLICK TO DOWNLOAD SAMPLE REPORT
The global phosphodiesterase inhibitors market is anticipated to record a notable CAGR over the forecast period i.e. 2020-2028. The market is segmented by drug class, type and application, out of which, the erectile dysfunction sub-segment of application segment is anticipated to hold leading shares in the phosphodiesterase inhibitors market on account of various factors, such as growing incidences of diseases such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, hyperlipidemia, and rising consumption of certain medicines and substance abuse can lead to erectile dysfunction. According to the World Health Organization (WHO), the global prevalence of erectile dysfunction is projected to increase from 150 million in 1995 to 320 million men in 2025. Additionally, the oral segment of the type sector is anticipated to witness a modest growth owing to factors such as low cost, and accurate dosage and stability.
Growth Drivers
Rising Prevalence Of Chronic Disease And Erectile Dysfunction
The phosphodiesterase inhibitors market is estimated to witness robust growth on account of the growing concern for the chronic diseases such as heart disease, stroke, diabetes, and prediabetes amongst individuals worldwide, which is raising the need for the treatment of the diseases. Further, increasing expenditure for the treatment of such chronic diseases is also anticipated to drive the growth of the market. According to the World Health Organization, 17.9 million people die each year from cardiovascular disease, an estimated 31% of all death worldwide. Moreover, escalating the prevalence of erectile dysfunction multiple factors, such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, and hyperlipidemia are estimated to support the development of the global market. Furthermore, rapid urbanization and the inherent lifestyle changes, along with high stress at the workplace are rendering young men more susceptible to erectile dysfunction.
Restraints
Potent Drug Interaction of Phosphodiesterase Inhibitors
The global phosphodiesterase inhibitors market is anticipated to hampered by factors such as potential drug interactions of PDE inhibitors, side-effects associated with PDE inhibitors, and the launch of generics.
Market Segmentation
Our in-depth analysis of the phosphodiesterase inhibitors market includes the following segments:
By Drug Class
By Type
By Application
By Region
On the basis of regional analysis, the phosphodiesterase inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
North America is projected to account for the highest share of the phosphodiesterase inhibitors market throughout the forecast period on account of factors such as the presence of large pharmaceutical companies and increasing lifestyle changes are contributing to the phosphodiesterase inhibitors market growth in the region.
The phosphodiesterase inhibitors market is further classified on the basis of region as follows:
Top Featured Companies Dominating the Market
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
